1
Bender Steven Lee, Broka Chris Allen, Campbell Jeffrey Allen, Castelhano Arlindo Lucas, Fisher Lawrence Emerson, Hendricks Robert Than, Sarma Keshab: Matrix metalloprotease inhibitors. Hoffmann La Roche, Agouron Pharma, June 25, 1997: EP0780386-A1 (167 worldwide citation)

Compounds of the formula: wherein: n is 0, 1 or 2; Y is hydroxy or XONH-, where X is hydrogen or lower alkyl; R is hydrogen or lower alkyl; R is hydrogen, lower alkyl, heteroalkyl, aryl, aralkyl, arylheteroalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroaralkyl, heteroarylheteroalkyl, heterocy ...


2
Love Robert A, Yu Xiu, Diehl Wade, Hickey Michael John, Parge Hans E, Gao Jingjin, Fuhrman Shella: (hcv) Ns5b rna polymerase and mutants thereof. Agouron Pharma, November 13, 2002: EP1256628-A2 (39 worldwide citation)

The present invention generally relates to viral RNA polymerases, which are essential to viral reproduction and propagation in a host. Viral RNA polymerases are known to play a role in the replication of the virus once it has infected its host. The present invention relates to mutants of native Hepa ...


3
Mroczkowski Barbara, Hickey Michael, Mctigue Michele Ann, Murray Brion William, Parge Hans, Sarup Jay, Zhu Jeff: Catalytic domains of the human hepatocyte growth factor receptor tyrosine kinase and methods for identification of inhibitors thereof. Agouron Pharma, September 25, 2002: EP1243596-A2 (10 worldwide citation)

The identification, isolation, purification, and characterization of the catalytic domain of the human hepatocyte growth factor receptor kinase (hHGFR) are described. A crystal structure of the hHGFR kinase domain is reported herein. This structure provides a three-dimensional description of the bin ...


4
Jones Terence R, Varney Michael D, Webber Stephen E, Appelt Krysztof, Marzoni Gifford: Antiproliferative cyclic compounds.. Agouron Pharma, May 2, 1990: EP0365763-A1 (10 worldwide citation)

A compound of formula (I) capable of inhibiting thymidylate synthase, a method for making such and a therapeutic process utilizing the compound of formula (I). b


5
Chong Wesley K M, Chu Shao Song, Duvadie Rohit R, Li Lin, Xiao Wei, Yang Yi: 4-aminothiazole derivatives, their preparation and their use as inhibitors of cyclin-dependent kinases. Agouron Pharma, June 19, 2002: EP1215208-A2 (7 worldwide citation)

This invention is directed to aminothiazole compounds of formula (I) wherein R is a substituted or unsubstituted group selected from : C1-6-alkyl; C1-6-alkenyl; C1-6-alkynyl; C1-6-alkoxyl; C1-6-alcohol; carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, cycloalkyl; carbocyclic ...


6
Chen Ping, Kan Chen Chen, Luo Chun, Margosiak Stephen, O& 039, Connor Patrick, Tempczyk Russel Anna, Nguyen Binh, Sarup Jay Chand, Gaur Smita, Anderson Mark Brian, Deng Ya Li, Lundgren Karen, Register James: Catalytic domain of the human effector cell cycle checkpoint protein kinase, chk1, materials and methods for identification of inhibitors thereof. Agouron Pharma, May 2, 2001: EP1096014-A2 (4 worldwide citation)

The present invention relates to the identification, isolation and purification of the catalytic domain of the human effector checkpoint protein kinase (hChk1). A 1.7 &cir& crystal structure of the hChk1 kinase domain in the active conformation is reported herein. The kinase domain of hChk1 and its ...


7
Inaba Takashi, Yamada Yasuki, Shanley James, Deason Michael: Process for producing amide derivatives and intermediate compounds. Japan Tobacco, Agouron Pharma, March 8, 2000: EP0984000-A1 (2 worldwide citation)

A process for producing amide derivatives represented by general formula (XV) or enantiomers thereof, novel intermediate compounds useful for producing these compounds, etc., and a process for producing the same, wherein each symbol is as defined in the specification. Compared with the conventional ...


8
Teng Min, Truesdale Larry Kenneth, Bhumralkar Dilip, Kiel Dan, Johnson Michael D, Thomas Christine, Jorgensen Anker Steen, Madsen Peter, Olesen Preben Houlberg, Knudsen Liselotte Bjerre, Petterson Ingrid Vivika, Cornelis de Jong Johannes, Behrens Carsten, Kodra Janos Tibor, Lau Jesper: Non-peptide glp-1 agonists. Novo Nordisk, Agouron Pharma, October 24, 2001: EP1147094-A1 (2 worldwide citation)

Novel non-peptide GLP-1 agonists, pharmaceutical compositions comprising them, use of the non-peptide GLP-1 agonists for the preparation of pharmaceutical compositions and methods for the treatment and/or prevention of disorders and diseases wherein an activation of the human GLP-1 receptor is benef ...


9
Anderson Mark Brian, Vazir Haresh N, Luthin David Robert, Paderes Genevieve Deguzman, Pathak Ved P, Christie Lance Christopher, Hong Yufeng, Tompkins Eileen Valenzuela, Li Haitao, Faust James: Non-peptide gnrh agents, methods and intermediates for their preparation. Agouron Pharma, June 13, 2001: EP1105120-A2 (1 worldwide citation)

Non-peptide GnRH agents capable of inhibiting the effect of gonadotropin-releasing hormone are described. Such compounds and their pharmaceutically acceptable salts, multimers, prodrugs, and active metabolites are suitable for treating mammalian reproductive disorders and steroid hormone-dependent t ...


10
Collins Michael Raymond, Tempczyk Russell Anna Maria, Hua Ye, Johnson Michael David, Bender Steven Lee, Kania Robert Steven, Borchardt Allen J, Braganza John F, Cripps Stephan James, Johnson Theodore Otto Jr, Luu Hiep The, Palmer Cynthia Louise, Reich Siegfried Heinz, Teng Min, Thomas Christine, Varney Michael David, Wallace Michael Brennan: Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use. Agouron Pharma, January 11, 2006: EP1614683-A1 (1 worldwide citation)

Indazole compounds that modulate and/or inhibit the activity of certain protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating tyrosine kinase signal transduction and thereby modulate and/or inhibit unwanted cell proliferation. The inv ...